Nelarabine

證據等級: L5

預測適應症: 1 個

Nelarabine: From T-Cell Malignancies to Relapsing-Remitting Multiple Sclerosis

One-Sentence Summary

Nelarabine is a purine nucleoside analogue chemotherapy agent selectively toxic to T-lymphocytes. The TxGNN model predicts it may be effective for Relapsing-Remitting Multiple Sclerosis (RRMS), an indication currently supported by no registered clinical trials and no published literature — this is a pure model-generated hypothesis at this stage.

Quick Overview

Item	Content
Original Indication	Not documented in the current evidence pack (no license/indication text available)
Predicted New Indication	Relapsing-Remitting Multiple Sclerosis
TxGNN Prediction Score	99.43%
Evidence Level	L5
Germany Market Status	Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack for this candidate. Based on general pharmacological knowledge, nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a purine nucleoside analogue. After conversion to its active triphosphate metabolite (ara-GTP), it is preferentially incorporated into DNA in T-lymphocytes — a selectivity driven by high deoxyguanosine kinase and low deaminase activity in T cells — causing chain termination and cell death. This T-cell selective cytotoxicity is the pharmacological basis for its established use as a chemotherapeutic agent.

RRMS is an autoimmune disease in which pathogenic, activated T-lymphocytes drive demyelination in the central nervous system. The mechanistic hypothesis linking nelarabine to RRMS would rely on its selective ability to deplete or suppress pathogenic T-cell populations — conceptually analogous to how other T-cell-depleting agents (e.g., cladribine, another purine analogue) have been repurposed for MS. However, this remains a mechanistic rationale only; the evidence pack contains no confirmatory clinical trial or literature evidence, so this connection should be treated as a hypothesis generated by the TxGNN model rather than an established or emerging clinical direction.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Germany Market Information

Nelarabine is currently not marketed in Germany under this evidence pack, and no marketing authorization records are available (total_licenses: 0).

Cytotoxicity

Nelarabine belongs to a known cytotoxic chemotherapy class (purine nucleoside analogue / antimetabolite), so this section applies.

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Purine nucleoside analogue, prodrug of ara-G)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Handling per cytotoxic drug regulations is expected given drug class; confirm against official labeling

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: There is currently zero clinical trial or literature evidence supporting the RRMS indication, and a blocking data gap exists for TFDA/official label warnings and contraindications, which prevents any S1 safety pre-assessment. The prediction score alone is insufficient to advance this candidate.

To proceed, the following is needed:

Official label safety data (warnings, contraindications) — currently blocking (DG001)
Confirmed mechanism of action (MOA) documentation (DG002)
Original approved indication(s) for this drug, to establish a baseline for repurposing rationale
At minimum, preclinical or mechanistic literature connecting nelarabine/T-cell depletion to autoimmune demyelinating disease before any further evaluation stage is considered
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.